NPI: 1417947466 · ENID, OK 73701 · Psychiatric Hospital Unit · NPI assigned 10/21/2005
Authorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
| Authorized Official | FILTON, STEVE (CFO, SENIOR VP) |
| NPI Enumeration Date | 10/21/2005 |
Other providers sharing the same authorized official: FILTON, STEVE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 6,950 | $594K |
| 2019 | 7,472 | $678K |
| 2020 | 4,423 | $371K |
| 2021 | 5,664 | $513K |
| 2022 | 13,449 | $1.17M |
| 2023 | 10,808 | $973K |
| 2024 | 5,691 | $554K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 6,324 | 6,235 | $1.51M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 9,178 | 9,104 | $1.47M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3,557 | 3,519 | $1.11M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2,205 | 2,157 | $280K |
| 36415 | Collection of venous blood by venipuncture | 9,585 | 8,706 | $130K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 350 | 199 | $59K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 112 | 112 | $39K |
| 96375 | Therapeutic injection; each additional sequential IV push | 887 | 854 | $37K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5,426 | 4,963 | $36K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 305 | 304 | $28K |
| 71045 | Radiologic examination, chest; single view | 1,969 | 1,930 | $24K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,435 | 748 | $21K |
| 80053 | Comprehensive metabolic panel | 2,312 | 2,262 | $20K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 186 | 183 | $11K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 105 | 93 | $11K |
| 97597 | 1,292 | 575 | $9K | |
| 80055 | 217 | 217 | $9K | |
| 81001 | 2,711 | 2,678 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1,288 | 1,238 | $7K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 244 | 244 | $5K |
| 71046 | Radiologic examination, chest; 2 views | 288 | 283 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 418 | 417 | $3K |
| 88312 | 40 | 26 | $3K | |
| 87653 | 91 | 91 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 371 | 368 | $3K |
| 86803 | 216 | 216 | $3K | |
| 81025 | 329 | 324 | $2K | |
| 84484 | 205 | 179 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 31 | 30 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 31 | 31 | $1K |
| 87430 | 94 | 94 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 12 | 12 | $1K |
| 87081 | 206 | 206 | $1K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 38 | 38 | $1K |
| 81002 | 362 | 256 | $977.75 | |
| 83690 | 155 | 151 | $852.07 | |
| 83605 | 69 | 61 | $699.91 | |
| 87420 | 55 | 55 | $687.66 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 30 | 30 | $665.00 |
| 85027 | 124 | 120 | $661.25 | |
| 81003 | 310 | 266 | $625.83 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 12 | 12 | $561.78 |
| 82950 | 118 | 118 | $481.18 | |
| 82962 | 162 | 67 | $292.84 | |
| 85018 | 130 | 130 | $263.54 | |
| 85014 | 130 | 130 | $263.54 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 12 | 12 | $187.26 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 12 | 12 | $187.26 |
| 83735 | 18 | 18 | $107.28 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 229 | 222 | $95.76 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 378 | 375 | $70.50 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 42 | 42 | $46.94 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 13 | 13 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 38 | 38 | $0.00 |